Delivery Order SPE2DB22D3016-SPE2DB25FAUD1
Award Date
4/17/25
Potential Completion Date
4/18/25
Potential Value
$2.7K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,239.50, is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. The contract has an ultimate completion date of January 22, 2025 and is a firm fixed-price contract. This contract does not have a set-aside designation, indicating it was competitively awarded....
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,180.16, is for the supply of HEMABATE 250 MCG/ML AMPULML, a specialty medication. The delivery order has a firm fixed-price pricing type and an ultimate completion date of December 2, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a ceiling value of $3,357.69 and a period of performance through February 14, 2025. The contract is a firm fixed-price type and was not set aside for any specific business category. AmerisourceBergen holds a...
This is a federal contract awarded by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a ceiling value of $2,543.70 and a firm fixed price pricing type. The contract is for HEMABATE 250 MCG/ML AMPUL/ML, a pharmaceutical product, with a period of performance through June 6, 2025. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract...
This is a Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of HEMABATE 250 MCG/ML AMPULML medical products. The contract has a ceiling value of $3,567.20 and an ultimate completion date of June 11, 2025. It is not designated as a set-aside contract. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a $10,661.67 firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEMABATE 250 MCG/ML AMPULML, a prescription medication. The contract has a period of performance through February 14, 2023 and is not set aside for any special business category. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of HEMABATE 250 MCG/ML AMPULML. The award, valued at $6,555.04, is a firm fixed-price Delivery Order with a completion date of February 16, 2024. This contract does not have a set-aside designation, indicating it was competitively awarded. AmerisourceBergen holds a significant Indefinite Delivery...
This federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a ceiling value of $23,749.20. The contract is a Firm Fixed Price Delivery Order with a period of performance through November 29, 2023. AmerisourceBergen, a major pharmaceutical distributor, holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division to provide a comprehensive...
This federal contract award is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The contract is a firm-fixed-price delivery order with a ceiling value of $2,054.69 and a period of performance ending on May 29, 2025. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is not set aside for any specific business type....
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, is for the delivery of HEMABATE 250 MCG/ML AMPULML medication. The $19,035.20 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA) and has a completion date of September 21, 2022. The award is not associated with a set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...